Research and Markets: Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market Research Report …

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/tsw9vr/asiapacific) has announced the addition of the "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017" report to their offering.

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Japan, China, India, South Korea, Malaysia, Indonesia, Australia, New Zealand, and Rest of Asia) to provide in-depth information on the Asia-Pacific scenario.

The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9 million in 2017 at a CAGR of 10.5%.

The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201(Tl-201), gallium-67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The PET radioisotopes market is dominated by fluoride-18 (F-18), followed by rubidium-82 (Rb-82).

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters has not been arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131(I-131), which is poised to grow at a CAGR of 7.7% from 2012 to 2017. The Asia-Pacific market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin's lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192).

Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are boosting the growth of the Asia-Pacific nuclear medicine market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The nuclear disaster at Fukushima nuclear plants in 2011 had a major impact on radioisotope production in Japan, which is the largest consumer market in the Asia-Pacific region. The Asia-Pacific region is insulated from the global crisis in Mo-99 supply since the production is based on local nuclear plants and OPAL reactor of ANSTO. ANSTO is deemed as the future solution to compensate global Mo-99 demand.

Major players in the radiopharmaceuticals market are Nihon Medi-Physics Co., Ltd. (Japan), Covidien PLC (U.S.), Fujifilm Corporation (Japan), ANSTO (Australia), and IBA S.A (Belgium).

The Asia-Pacific stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The Asia-Pacific stable isotopes market was estimated at $56.1 million in 2012 and is expected to cross $100.0 million by 2017 at a CAGR of 12.6%.

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Sigma Aldrich (U.S.) in 2012.

Go here to read the rest:

Research and Markets: Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market Research Report ...

Despite Lokayukta dampener, Gouds get fish 'medicine' ready

Posted on by

Hyderabad, June 6 (IANS) The Bathini Goud family here has begun preparations for administering the fish "prasadam" (medicine) for asthma patients here June 8-9, even as the Lokayukta has directed the government not to sponsor such events.

The family members were busy Thursday getting ready the herbal paste, which is inserted into the mouth of a live murrel fish fingerling, and slipped into the mouth of the patient as part of the traditional cure for asthma.

"As the government has given us permission to distribute the prasadam at Exhibition Grounds, we are continuing our preparations," Bathini Harinath Goud told IANS Thursday.

He said they had not yet received copies of the Lokayukta order.

"We don't want to comment without going through the order," he said. "We are continuing the arrangements, as we don't want to inconvenience guests coming from outside the city and the state," Goud said.

Lokayukta Justice B. Subhashan Reddy had Wednesday asked the government not to sponsor or support the event, saying there is no scientific proof that the substance cures asthma. While observing that it is only a superstition, the ombudsman said Goud can continue practising it as there is no law restraining such practices.

Justice Reddy, however, made it clear that public funds should not be used for the event. He said Goud should make his own arrangements for the supply of fish.

Every year, the fisheries department supplies fingerlings to thousands of patients coming from different parts of the country.

The Lokayukta has also directed that the family, and not the government, should pay Rs.2.69 lakh to the Exhibition Society for using the grounds for the event, and suggested that the society obtain an undertaking from Goud that he will pay the amount in a month.

Since only two days are left for the annual event to begin, the Lokayukta allowed the government to make arrangements like supply of water, sanitation, ambulances and security this year, and asked the government not to make such arrangements from next year.

View original post here:

Despite Lokayukta dampener, Gouds get fish 'medicine' ready

New Data on Concierge Physician Salaries Released by Concierge Medicine Today

Posted on by

(PRWEB) June 06, 2013

The Concierge Medicine Research Collective, the independent health care research depository of the concierge and direct primary care industry's trade publication, Concierge Medicine Today, has just released new data summarizing concierge medicine physician salaries. The data is based on surveys, polling analysis and verbal responses received from concierge doctors across the U.S. from 2009-2012. Here are some of the highlights:

The Collective estimates concierge medicine and direct care physicians number approximately 5,000-5,5000 physicians and/or physician clinics across the U.S. This according to in-depth review and recent examination of the national marketplace as well as interviews with corporate industry leaders. The Collective also found that the states which appear to be the leanest from a concierge physician service population perspective are in areas such as: Hawaii; Idaho; Iowa; Mississippi; Maine; New Hampshire and South Dakota. Furthermore, The Collective found the number of patients who are seeking concierge medical care in the past 24-months is far greater than the actual number of primary care and family practice concierge doctors available to serve them. Concierge medical services in rural areas like Idaho, North Dakota, South Dakota, Alaska, Hawaii, Louisiana and Mississippi are in shortly supply. Often times, they have found that there are less than half-a-dozen practitioners to serve an entire state.

"Growth in any service industry, particularly healthcare depends largely on consumer spending. Concierge medicine and it's cousin, direct primary care are approaching a tipping point," says Michael Tetreault, Executive Director of The Collective and Editor of the industry's trade publications, Concierge Medicine Today and The Direct Primary Care Journal. "Doctors are now deciding between what they have to do and what they want to do."

2013 Concierge Medicine Physician Compensation Data

When compared to traditional, insurance-based physicians working in a hospital setting, Today's Hospitalist conducted their own limited survey of non-concierge hospitalist physicians and found that the salary ranges very widely with some hospitalists making between $150,000 to $227,000 in annual income.

2013 Concierge Medicine Physician Compensation Data

It's also important to note that Concierge Medicine and Cash Only practices are on the rise (albeit a slow one) but joining ACOs jumped up from 3% to 16%, this from a 2013 MedScape Survey.

Concierge Medicine Career Satisfaction

"I think the most powerful piece of this data is this one that speaks to career satisfaction," adds Tetreault. "The modern-day primary care career path is more challenging today because things like low reimbursement, high-overhead and liability insurance only bother you when you do work that matters. The good news today is that the concierge medicine and direct primary care business models provide doctors with hope, a practical billing pattern, price transparency and trust with patients. This is a career path physicians can trust and it's a proven business model that patients value."

Read more here:

New Data on Concierge Physician Salaries Released by Concierge Medicine Today

Boston University School of Medicine, Department of Medicine, Wins 2013 Ventana Research Leadership Award for Its …

Posted on by

WALTHAM, Mass.--(BUSINESS WIRE)--

The Boston University School of Medicine (BUSM), Department of Medicine, today announced that it is being honored, along with Actifio, the radically simple copy data management company, as a winner of the 2013 Ventana Research Leadership Award for Sustainability.

BUSMs Department of Medicine was selected to receive this award from Ventana Research analysts based on the impact of its implementation of Actifios Copy Data Storage. The implementation allowed the Department of Medicine to sustain IT operations more efficiently; protecting hundreds of terabytes of data without having to protect all the copies, thus dramatically reducing the amount of storage needed. With Actifio, the Department of Medicine has reduced its total storage costs by 10X, its data by 50 percent and its bandwidth by as much as 70 percentsaving nearly $1.5 million on hardware expenditures for backup storage.

We congratulate Boston University Medical Center for receiving the 2013 Ventana Research Business Technology Leadership Award in Sustainability for its use of Actifio to help streamline the storage and use of data more intelligently. Their approach allowed them to avoid creating more storage networks that consume more resources and footprint in the IT organization. I'd also like to congratulate Actifio for making it possible for their customers to derive such significant value and help organizations like Boston University Medical Center adapt their IT and data needs to be more sustainable in its operations and use of technology. Mark Smith, CEO and Chief Research Director, Ventana Research.

Boston University Medical Campus is home to the university's Schools of Medicine, Public Health and Dental Medicine, as well as the Division of Graduate Medical Sciences. It serves more than 3,400 full- and part-time students. As an academic medical research center, researchers move quickly from project to project, but their findings and the data they generate must be stored and protected as the need to access it may arise at any time. Storing and protecting previously generated data, and related copy data for backup and disaster recovery efforts, in countless different formats and standards, is a complex and burdensome task. To balance compliance while managing a tremendous amount of data that needed to be effectively stored, shared, analyzed and managed, the Medical School turned to Actifios Copy Data Storage solution.

Actifios Copy Data Storage has allowed the BUSM Department of Medicine to focus on medical research, not wrangling copy data, said Dr. John Meyers, Assistant Professor of Medicine and Director of Technology for the Department of Medicine. In addition to streamlining the copy data problem, the Department often uses identifiable patient data for approved studies; Actifio afforded faculty access to patient information without allowing the data to leave the school.

The Ventana Research Leadership Awards recognize and promote individuals and organizations that have contributed to advancing the use of technology in their organizations bringing together people, process, information and technology to achieve the best potential outcomes. As part of the scoring process and methodology, Ventana Research examined submissions and nominations from the research team to assess, score and select the technology that has the best impact in that specific category.

At the time that the Department of Medicine set out to wrangle their copy data challenge, there were no solutions specifically tailored for the research/life sciences vertical to safely store, share, analyze, recall and minimize the large amounts data created in the discovery process, said Ash Ashutosh, Actifio CEO. Dr. Meyers was one of Actifios earlier users and we worked closely with him to meet his unique needs. Were humbled that his organization has now been recognized for their innovation and sustainability in implementing a more efficient data management strategy.

About the Ventana Leadership Award The 2013 Ventana Research Leadership Awards recognize individuals and organizations that have advanced business leadership by effectively utilizing their people, processes, information and technology to achieve the best outcomes. The Leadership Awards showcase not only organizations but also the leaders and pioneers who have contributed to their organizations' successes. These practitioners exemplify the fact that delivering business success requires the successful efforts of a team guided by strong, visionary, effective leadership.

The awards are judged by the analysts at Ventana Research, an industry-renowned research team with hundreds of years of experience in business and technology. The team evaluated each submission to assess the organization's use of people, processes, information and technology, the best practices it developed and the project's business impacts on the organization in 2012 and 2013 as well as the projected value in 2014.

Read this article:

Boston University School of Medicine, Department of Medicine, Wins 2013 Ventana Research Leadership Award for Its ...

Upstate medical school taken off probation by national accreditation group

Posted on by

Syracuse, N.Y. -- Upstate Medical University's medical school has been removed from probation by a national accreditation group.

Dr. David Duggan, dean of the medical school, told faculty and students today that the Liaison Committee on Medical Education -- LCME for short -- notified him in a Wednesday night phone call of its decision to lift Upstate's probationary status.

The LCME put Upstate on probation in February of 2012 because of concerns over how the school was run, its curriculum and other issues.

Upstate officials subsequently set out to fix the problems identified by LCME. Dr. Steven J. Scheinman resigned as dean after LCME recommended probation for Upstate. Duggan stepped in as interim dean and was appointed dean in March. The medical school has remained fully accredited during the probationary period.

Losing accreditation would have been a death penalty for Upstate because the school would no longer be able to offer medical degrees.

Upstate spokesman Darryl Geddes said the school expects to learn more details of the LCME's decision over the next week.

"We will have more details when the formal letter is in hand, but I did not want to wait in sharing this news with the many, many people here who have worked so diligently to achieve this outcome," Duggan wrote in a note to faculty and students.

One of LCME's major criticisms was Upstate's lack of a central committee with the authority to make changes in the school's courses.

The LCME also was concerned over a cheating scandal that occurred in 2012 involving fourth-year medical students who helped each other on online quizzes in a required medical literature course.

Accreditation is important because it shows that a medical school meets national standards. Graduating from an LCME-accredited school is a condition for a medical license in most states.

Original post:

Upstate medical school taken off probation by national accreditation group

Jeep Liberty Dealer Bay St Louis, MS | Jeep Liberty Dealership Bay St Louis, MS – Video

Posted on by


Jeep Liberty Dealer Bay St Louis, MS | Jeep Liberty Dealership Bay St Louis, MS
http://www.lakeshorechrysler.com/index.htm Make your way over to Lakeshore Chrysler Dodge Jeep in Slidel, LA. We have an awesome inventory on new and used Je...

By: Lakeshore CDJ

Originally posted here:

Jeep Liberty Dealer Bay St Louis, MS | Jeep Liberty Dealership Bay St Louis, MS - Video